GENEVA, Oct. 22 -- ERASCA, INC. filed a patent application (US2026/012663) for “RAS AND CTLA-4 INHIBITORS COMBINATION THERAPY FOR THE TREATMENT OF CANCER”. With publication no. WO/2026/165003, here are the other details related to the patent application:
Kind: Correction of entry in Section I of the PCT Gazette [A8]
IPC: A61K 31/504
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....